C-MGDDImmorta Bio
senescent cells, stem cells, personalized therapeutics
replacementreplacingcell therapy
Loading
Loading section...0-100 chain-logic scale · 15 dimensions · scored on public evidence
←All companiesC-MGDD
C-MGDDC-MGDDsenescent cells, stem cells, personalized therapeutics
0-100 chain-logic scale · 15 dimensions · scored on public evidence
Immorta Bio Announces Publication of International Patent Application for SenoVax™, a First-in-Class Senolytic Immunotherapy Accessibility Statement Skip Navigation Resources Investor Relations Journalists Agencies Client Login Send a Release News Products Contact Search Search When typing in this field, a list of search results will appear and be automatically updated as you type. Searching for your content... No results found. Please change your search terms and try again. News in Focus Browse News Releases All News Releases All Public Company English-only News Releases Overview Multimedia G … Blog Journalists RSS Immorta Bio Announces Publication of International Patent Application for SenoVax™, a First-in-Class Senolytic Immunotherapy News provided by Immorta Bio Inc. Nov 25, 2025, 08:11 ET Share this article Share to X Share this article Share to X Targeting the Root Causes of Aging Demonstrates Powerful Anti-Cancer Activity Across Multiple Tumor Models MIAMI BEACH, Fla. , Nov. 25, 2025 /PRNewswire/ -- Immorta Bio Inc., a scientific longevity company pione … Aging as Disease™ , today announced the publication of its international patent application PCT/WO2025184665[1], entitled "Senescence Vaccine." Continue Reading Dr. Thomas Ichim, President and Chief Scientific Officer of Immorta Bio The application describes Immorta Bio's proprietary approach to stimulating the immune system to selectively eliminate senescent cells: the dysfunctional "old cells" that drive aging, inflammation, organ failure, and support tumor growth. Removing … improvement in healthspan These results, along with the publication of this PCT application, strengthen Immorta Bio's position as the only company developing a dual-platform solution to aging that also treats its most lethal diseases. About Immorta Bio Immorta Bio Inc. is a scientific longevity company developing two complementary platforms to reverse aging and treat age-related diseases: SenoVax™, a first-in-class senolytic immunotherapy that eliminates senescent cells, … 8/v1 3 https://www.targetedonc.com/view/senovax-investigational-new-drug-application-filed-with-the-fda-in-nsclc SOURCE Immorta Bio Inc. 21 % more press release views with Request a Demo × Modal title Also from this source Immorta Bio Publishes Over 70% Increased Longevity in Aging Animals by its Patented Therapeutic Combination Immo
PR Newswire: press release distribution, targeting, monitoring and marketing | Boris Reznik | 10 comments LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in, you
The Science of Aging Home About Us Mission People Careers Science Science of Aging SenoVax™ StemCellRevivify™ Intellectual Property Publications News & Resources News Decks Pipeline Main Pipeline Contact Us About Mission People Careers Contact Science Science of Aging SenoVax™ StemCellRevivify™ Intellectual Property Publications News & Resources News Decks Pipeline Main Pipeline Contact The Science of Aging Reverse Aging. Rejuvenate Organs. Eliminate Cancer. Aging was once thought to be inevitable — a passive decline written into our DNA. Today, we know better. Aging is an active biolo
Patent filed for Immorta Bio’s new senolytic vaccine Skip to content News Data Podcast Clinics News Data Podcast Clinics Search Investment Biotech Research AI/Tech Supplements Clinics Ecosystem LT Wire Investment Biotech Research AI/Tech Supplements Clinics Ecosystem LT Wire Advertise NEWSLETTER News Data Podcast Clinics News Data Podcast Clinics Investment Biotech Research AI/Tech Supplements Clinics Ecosystem LT Wire Investment Biotech Research AI/Tech Supplements Clinics Ecosystem LT Wire About Contact About Contact Advertise nEWSLETTER Search Search TrimTech adds $14m in fundi... Winona st … y biotech Immorta Bio has announced the publication of its international patent application for SenoVax, a first-in-class senolytic immunotherapy designed to eliminate senescent cells, the dysfunctional “old cells” that accumulate with age and drive chronic disease [ 1 ]. The published patent outlines a novel “senescence vaccine” strategy that aims to train the immune system to identify and destroy these problem cells precisely. Unlike traditional senolytic drugs, which chemi … e menopause symptoms simultaneously GARM Clinic launches first Klotho longevity residency in Roatan Cognito’s wearable device boosts brain proteins linked to Alzheimer’s protection Lys Therapeutics raises over $27m to advance new treatments for Parkinson’s and stroke RELATED ARTICLES Stem cell banking partnership targets future of longevity Rapalogix raises $20m for longevity skin health Insilico’s $2.5b AI drug discovery deal targets neuroimmune failure You
Immorta Bio Advances Lung Cancer Immunotherapy with Peer-Reviewed Animal Data on Senolytic Vaccine Home About Us Mission People Careers Science Science of Aging SenoVax™ StemCellRevivify™ Intellectual Property Publications News & Resources News Decks Pipeline Main Pipeline Contact Us About Mission People Careers Contact Science Science of Aging SenoVax™ StemCellRevivify™ Intellectual Property Publications News & Resources News Decks Pipeline Main Pipeline Contact Immorta Bio Advances Lung Cancer Immunotherapy with Peer-Reviewed Animal Data on Senolytic Vaccine December 18, 2024 Breakth … sting treatments." Immorta Bio has filed an Investigational New Drug (IND) application for SenoVax™ and anticipates initiating clinical trials in the coming months. Dr. Boris Reznik, Chairman and CEO of Immorta Bio, noted, "Immorta Bio is advancing rapidly where options are limited. By demonstrating the clinical feasibility of targeting senescent cells, we plan to expand this breakthrough approach beyond cancer to other indications." The full research article c
Tietosuojavalintasi guce guce Tietosuojasi on meille tärkeää Tietosuojavalintojasi käytetään kaikissa Yahoo-konsernin tarjoamissa sivustoissa ja sovelluksissa. Yahoo käyttää evästekäytännöstämme ."> Evästeet Evästeiden (sekä vastaavien tekniikoiden, esimerkiksi verkkotallennuksen) avulla verkkosivustojen sovellusten ylläpitäjät voivat tallentaa ja lukea laitteesi tietoja. Lue lisää evästekäytännöstämme . evästeitä seuraaviin tarkoituksiin: tarjotaksemme sivustomme ja sovelluksemme sinulle todentaaksemme käyttäjät, estääksemme roskapostia ja väärinkäytöksiä sekä toteuttaaksemme tietoturvatoimia
Immorta Bio Inc, a Longevity Company, Announces a Significant Breakthrough in Treatment of Liver Failure Home About Us Mission People Careers Science Science of Aging SenoVax™ StemCellRevivify™ Intellectual Property Publications News & Resources News Decks Pipeline Main Pipeline Contact Us About Mission People Careers Contact Science Science of Aging SenoVax™ StemCellRevivify™ Intellectual Property Publications News & Resources News Decks Pipeline Main Pipeline Contact Immorta Bio Inc, a Longevity Company, Announces a Significant Breakthrough in Treatment of Liver Failure May 23, 2024
Immorta Bio’s Research Points to a Potential Pathway Toward "Re-Awakening" Coma Patients Home About Us Mission People Careers Science Science of Aging SenoVax™ StemCellRevivify™ Intellectual Property Publications News & Resources News Decks Pipeline Main Pipeline Contact Us About Mission People Careers Contact Science Science of Aging SenoVax™ StemCellRevivify™ Intellectual Property Publications News & Resources News Decks Pipeline Main Pipeline Contact Immorta Bio’s Research Points to a Potential Pathway Toward "Re-Awakening" Coma Patients PR Newswire October 14, 2
Breakthrough Immorta Bio Study Collaboration With TAM Global Increases Life Span In Mice over 70% Using Novel Combination Senolytics Accessibility Statement Skip Navigation Resources Investor Relations Journalists Agencies Client Login Send a Release News Products Contact Search Search When typing in this field, a list of search results will appear and be automatically updated as you type. Searching for your content... No results found. Please change your search terms and try again. News in Focus Browse News Releases All News Releases All Public Company English-only News Releases Overview Mult … tform Login ProfNet Data Privacy Do not sell or share my personal information : Submit via [email protected] Call Privacy toll-free: 877-297-8921 Contact PR Newswire Products About My Services All News Releases Platform Login ProfNet Call PR Newswire at 888-776-0942 Terms of Use Privacy Policy Information Security Policy Site Map RSS Cookies Copyright © 2026 Cision US Inc. --> -->
Immorta Bio's Anti-Aging Stem Cell Product Shows Superiority in Rheumatoid Arthritis in Preclinical Studies Home About Us Mission People Careers Science Science of Aging SenoVax™ StemCellRevivify™ Intellectual Property Publications News & Resources News Decks Pipeline Main Pipeline Contact Us About Mission People Careers Contact Science Science of Aging SenoVax™ StemCellRevivify™ Intellectual Property Publications News & Resources News Decks Pipeline Main Pipeline Contact Immorta Bio's Anti-Aging Stem Cell Product Shows Superiority in Rheumatoid Arthritis in Preclinical Studi
Immorta Bio's SenoVax™ Reduces Growth and Stops Metastasis of Aggressive Breast Cancer Using its First-In-Class Immune Stimulatory Therapy Home About Us Mission People Careers Science Science of Aging SenoVax™ StemCellRevivify™ Intellectual Property Publications News & Resources News Decks Pipeline Main Pipeline Contact Us About Mission People Careers Contact Science Science of Aging SenoVax™ StemCellRevivify™ Intellectual Property Publications News & Resources News Decks Pipeline Main Pipeline Contact Immorta Bio's SenoVax™ Reduces Growth and Stops Metastasis of Aggressive B … our team of scientists and collaborators who are working at a breakneck pace to apply lessons learned from our work in longevity to chronic health conditions such as cancer.” Said Dr. Boris N Reznik, Chairman and CEO of Immorta Bio. “To our knowledge, SenoVax is the first immunotherapy that works by removing senescent cells that surround the tumor. Once these are removed, the body does what it does best: defend itself.” About Immorta Bio Immorta Bio Inc. is a scientific longe … t-senovax [2] https://www.targetedonc.com/view/senovax-investigational-new-drug-application-filed-with-the-fda-in-nsclc [3] https://www.prnewswire.com/news-releases/senovax-breakthrough-cancer-immunotherapy-preserves-immune-function-post-chemotherapy-in-animal-models-302239460.html Read Full Article Share this post Never Miss A Headline Subscribe to Immorta Bio's Newsletter Thank you! Your submission has been received! Oops! Something went wrong while submitting the fo
Just dropped: A visionary joins the... - Bob Gordon Films Facebook Log In Bob Gordon Films's Post Bob Gordon Films October 24, 2025 · Shared with Public Just dropped: A visionary joins the mission. As part of the Strategic Advisory Board for Immorta Bio Inc , I had the honor of directing and producing the official announcement welcoming Dr. Gilberto Lopes—a global leader in immuno-oncology—to the team. Dr. Lopes helped bring Keytruda® to lung cancer patients worldwide. Now he’s joining Immorta Bio’s mission to push the boundaries of cancer therapy and healthy human longevity. Dr Lopes is
Immorta Bio Reports Activity of SenoVax™ in CTE Model Home About Us Mission People Careers Science Science of Aging SenoVax™ StemCellRevivify™ Intellectual Property Publications News & Resources News Decks Pipeline Main Pipeline Contact Us About Mission People Careers Contact Science Science of Aging SenoVax™ StemCellRevivify™ Intellectual Property Publications News & Resources News Decks Pipeline Main Pipeline Contact Immorta Bio Reports Activity of SenoVax™ in CTE Model PR Newswire September 24, 2025 Newly filed patent describes an unexpected senescence–CTE link; SenoVax™-induced ant … d Treating Aging as Disease™," today announced the filing of a U.S. patent application covering unexpected preclinical findings that senolytic approaches—including the company's senolytic immunotherapy SenoVax™—improved outcomes in experimental models of chronic traumatic encephalopathy (CTE). CTE is a progressive neurodegenerative condition associated with repetitive head impacts in athletes, military veterans, and others. It is characterized by mood and behavior c
%PDF-1.7 %���� 1 0 obj >>> endobj 2 0 obj > endobj 3 0 obj > endobj 4 0 obj /LastModified /NumberOfPageItemsInPage 2/NumberofPages 1/OriginalDocumentID /PageItemUIDToLocationDataMap >/PageTransformationMatrixList >/PageUIDList >/PageWidthList >>>>>/Resources >/ExtGState >/Font >/ProcSet[/PDF/Text/ImageC/ImageI]/Properties >/XObject >>>/Rotate 0/StructParents 0/TrimBox[ 0 0 1008 612]/Type/Page>> endobj 5 0 obj >stream H��VmoG�~�b>�/���U n�j㚋����+\ Y�����=�Dm�Ԗ����gޞ����r�y[����x � ��ݮ�Y=� ^}�������8�����@������B˸����Yzˤ�^h e�Y��������LS*����A�R�6e��D����9ޡӂ>����c�\� … sh) 2025-01-06T10:58:52-08:00 2025-01-06T10:58:52-08:00 Adobe PDF library 17.00 application/pdf BTS25_Schedule_Cover 1 True False 14.000000 8.500000 Inches Futura-Medium Futura Medium TrueType 16.0d2e1 False Futura.ttc Futura-Bold Futura Bold TrueType 16.0d2e1 False Futura.ttc FuturaStd-CondensedExtraBd Futura Std Extra Bold Condensed Open Type Version 2.025;PS 002.000;hotconv 1.0.50;makeotf.lib2.0.16970 False FuturaStdCondensedExtraBd.otf FuturaStd-Book Futura Std Book Open
Facebook Explore the things you love . Log into Facebook Email or mobile number Password Log in Forgot password? Create new account English (US) فارسی العربية Türkçe Deutsch Français (France) Polski More languages… Sign Up Log In Messenger Facebook Lite Video Meta Pay Meta Store Meta Quest Ray-Ban Meta Meta AI Instagram Threads Privacy Policy Privacy Center About Create ad Create Page Developers Careers Cookies Ad choices Terms Help Contact Uploading & Non-Users Meta © 2026
All Health News and Press Releases from PR Newswire Accessibility Statement Skip Navigation Resources Investor Relations Journalists Agencies Client Login Send a Release News Products Contact Search Search When typing in this field, a list of search results will appear and be automatically updated as you type. Searching for your content... No results found. Please change your search terms and try again. News in Focus Browse News Releases All News Releases All Public Company English-only News Releases Overview Multimedia Gallery All Multimedia All Photos All Videos Multimedia Gallery Overview T … ifornia... 08:00 ET Luma's Executive Sessions Recognized as a 2026 Swaay.Health Award Winner for Event of the Year Health system executives hear from dozens of promising AI vendors, but sorting what's real from the hype is hard from a conference seat. Luma... 08:00 ET Spear Education Announces Live-Patient Seminar on Anterior Implant Esthetics Spear Education, the leading provider of advanced dental education and dental workforce enablement solutions, today announces its Ante … with the University of Georgia College of... 07:03 ET Veeva Introduces New EHS Application for Proactive Risk Management and Intelligent Automation Veeva Systems (NYSE: VEEV) today announced Veeva EHS, a new application in Veeva Quality Cloud for environmental, health, and safety. With Veeva EHS, ... 07:00 ET Mwyngil Therapeutics Announces Positive in vivo Proof of Concept Data for First-in-Class GPR75 Inverse Agonist in Obesity and Cardiometabolic Disease. Mwyngil Therapeut … CPC-led social welfare development in Shanghai for years: Nepali Magnolia Gold Award recipient Sunlight streams through a glass window into a consultation room at a private hospital in Shanghai. On a table by the window sit an array of trophies ... 03:00 ET DAVION HEALTHCARE ANNOUNCES PROPOSED ACQUISITION OF HUMASKAN AND ESTABLISHMENT OF UK FINANCE SUBSIDIARY TO SUPPORT STRATEGIC ACQUISITION PROGRAMME Davion Healthcare Plc ("Davion" or the "Company"), a n … 定領導力及創新演講者 Gaby Natale 於 Powerful Women Summit 發表開幕主題演講 Gaby Natale 是三度榮獲 Emmy® Award（艾美獎）的記者、暢銷作家、全球主題演講者兼 女性健康科技創辦人，她於 Forbes Powerful Women Summit（福布斯傑出女性峰會）發表開幕主題演講。該峰會是 Forbes... Jun 24, 2026, 21:27 ET Proliant Health & Biologicals setzt mit AlbufreeDX neue Maßstäbe bei Albumin: Konsistentes, tierfreies rekombinantes Humanalbumin Prolian
Instagram See everyday moments from your close friends . Log into Instagram Mobile number, username or email Password Log in Forgot password? Log in with Facebook Create new account Meta About Blog Jobs Help API Privacy Terms Locations Popular Instagram Lite Meta AI Threads Contact Uploading & Non-Users Meta Verified English Down chevron icon Afrikaans العربية Čeština Dansk Deutsch Ελληνικά English English (UK) Español (España) Español فارسی Suomi Français עברית Bahasa Indonesia Italiano 日本語 한국어 Bahasa Melayu Norsk Nederlands Polski Português (Brasil) Português (Portugal) Русский Svenska ภ
Immorta Bio's Newest IP + Preclinical Progress: Advancing Mitochondrial Regeneration Strategy Home About Us Mission People Careers Science Science of Aging SenoVax™ StemCellRevivify™ Intellectual Property Publications News & Resources News Decks Pipeline Main Pipeline Contact Us About Mission People Careers Contact Science Science of Aging SenoVax™ StemCellRevivify™ Intellectual Property Publications News & Resources News Decks Pipeline Main Pipeline Contact Immorta Bio's Newest IP + Preclinical Progress: Advancing Mitochondrial Regeneration Strategy PR-Newswire October 24, 2 … nd Aging as Disease™," today announced new data and the filing of a patent application demonstrating regeneration of heart, brain, and liver tissues using mitochondria isolated from personalized mesenchymal stem cells (pMSC) generated through the Company's proprietary StemCellRevivify™ platform. The new data disclosed in the patent application show that pluripotent stem cells can be generated from the blood of aged mice and differentiated into "young" pMSC
Phoenix and MD Anderson expand cell therapy safety switches Skip to content News Data Podcast Clinics News Data Podcast Clinics Search Investment Biotech Research AI/Tech Supplements Clinics Ecosystem LT Wire Investment Biotech Research AI/Tech Supplements Clinics Ecosystem LT Wire Advertise NEWSLETTER News Data Podcast Clinics News Data Podcast Clinics Investment Biotech Research AI/Tech Supplements Clinics Ecosystem LT Wire Investment Biotech Research AI/Tech Supplements Clinics Ecosystem LT Wire About Contact About Contact Advertise nEWSLETTER Search Search Leal Therapeutics doses fir... An
Stemora Receives TEDCO Investment for Cartilage Regeneration | Srujana C. posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in, you a … or more information about TEDCO’s Pre-Seed Rural Business Innovation Initiative Fund, visit https://lnkd.in/ed92WDRJ #stemcell #TEDCO #lifesciences #biotech #Maryland 87 18 Comments Like Comment Share Copy LinkedIn Facebook X Bavneet K. 1w Report this comment Really exciting news, Srujana ! Congratulations to you and your team. It's wonderful to see Stemora growing and gaining support for such meaningful work. Wishing you continued success and many more milestones ahead. 🌟🥳 … or more information about TEDCO’s Pre-Seed Rural Business Innovation Initiative Fund, visit https://lnkd.in/ed92WDRJ #stemcell #TEDCO #lifesciences #biotech #Maryland 36 5 Comments Like Comment Share Copy LinkedIn Facebook X To view or add a comment, sign in Jack (Jie) Huang MD, PhD 3d Report this post 🟥 In Vivo CAR-T Engineering for Scalable Cell Therapy Production What if CAR-T cells could be manufactured inside the patient instead of inside a factory? In vivo CAR-T engine
All Biotechnology News and Press Releases from PR Newswire Accessibility Statement Skip Navigation Resources Investor Relations Journalists Agencies Client Login Send a Release News Products Contact Search Search When typing in this field, a list of search results will appear and be automatically updated as you type. Searching for your content... No results found. Please change your search terms and try again. News in Focus Browse News Releases All News Releases All Public Company English-only News Releases Overview Multimedia Gallery All Multimedia All Photos All Videos Multimedia Gallery Ove … :00 ET RBL LLC Announces Launch of SteerBio with an up to $18.2 Million Federal Award to Pioneer a Curative Therapy for Lymphedema RBL LLC, a pioneering biotech venture creation studio dedicated to rapidly building companies based on breakthrough medical technologies, today... Mar 05, 2026, 08:00 ET Panome Bio Launches Exposomics Services to Measure the Chemical Drivers of Human Disease Panome Bio, a leading multi-omics contract research organization, today announced the laun … develop first regenerative therapy for lymphedema receives up to $18.2M federal award team of researchers led by Rice University bioengineer Omid Veiseh has been awarded $18.2 million in funding from the Advanced Research Projects... Mar 04, 2026, 10:27 ET Frontage Laboratories Completes Acquisition of Teddy Lab, Strengthening Global Central Laboratory Capabilities Frontage Laboratories, Inc. ("Frontage"), a leading global CRO/CDMO, today announced the completion of … fter years of rigorous clinical, regulatory, and... Mar 03, 2026, 11:03 ET MACC Fund Commits $11.5 Million to Propel Pediatric Cancer Research at Versiti Blood Research Institute The MACC Fund has committed $11.5 million to advance pediatric cancer research at the Versiti Blood Research Institute, strengthening a long-standing ... Mar 03, 2026, 11:00 ET bitBiome Announces Major Collaboration Agreement in Commercial-Scale Bio-Manufacturing of Food-Grade Ingredient bitBiome, a … ated to make your job easier. In need of subject matter experts for your story? Submit a free ProfNet request and find the sources you need. LEARN MORE « 37 --> 37 38 --> 38 39 --> 39 40 --> 40 41 --> 41 » Making a selection with these dropdown will cause content on this page to change. News listings will update as each option is sele
Dr. Russel Kaufman Joins Immorta Bio's Board Of Directors | citybiz Skip to content citybiz Cities Atlanta Baltimore Boston Charlotte Raleigh Chicago Cleveland Dallas Denver Detroit Global Houston Indianapolis Los Angeles New York Philadelphia Phoenix Pittsburgh Portland San Diego San Francisco Seattle South Florida Washington DC Channels Q&A citybiz+ People Commercial Real Estate General Business Mergers & Acquisitions Financial Services / Investment Firms Venture Capital Internet / Technology Law Bylines Thought Leadership Accounting Architecture and Construction Residential Rea
Instagram See everyday moments from your close friends . Log into Instagram Mobile number, username or email Password Log in Forgot password? Log in with Facebook Create new account Meta About Blog Jobs Help API Privacy Terms Locations Popular Instagram Lite Meta AI Threads Contact Uploading & Non-Users Meta Verified English Down chevron icon Afrikaans العربية Čeština Dansk Deutsch Ελληνικά English English (UK) Español (España) Español فارسی Suomi Français עברית Bahasa Indonesia Italiano 日本語 한국어 Bahasa Melayu Norsk Nederlands Polski Português (Brasil) Português (Portugal) Русский Svenska ภ
Immorta Bio Presents SenoVax™ Mediated Tumor Remission Data at International Biotechnology Conference Home About Us Mission People Careers Science Science of Aging SenoVax™ StemCellRevivify™ Intellectual Property Publications News & Resources News Decks Pipeline Main Pipeline Contact Us About Mission People Careers Contact Science Science of Aging SenoVax™ StemCellRevivify™ Intellectual Property Publications News & Resources News Decks Pipeline Main Pipeline Contact Immorta Bio Presents SenoVax™ Mediated Tumor Remission Data at International Biotechnology Conference PR Newswire March 1 … s Reznik, Chairman and CEO of Immorta Bio. "Our development strategy is to apply longevity-associated technologies to address unmet medical needs that can provide answers in months not decades." About Immorta Bio : Immorta Bio Inc., a scientific longevity company focused on "Treating Diseases of Aging and Treating Aging as Disease™," leverages anti-aging technologies to tackle pressing medical challenges, from advanced cancers to other age-related conditio
Orna Therapeutics Acquired by Eli Lilly in $2.4B Deal | Biologics Workshop posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in, you
Instagram See everyday moments from your close friends . Log into Instagram Mobile number, username or email Password Log in Forgot password? Log in with Facebook Create new account Meta About Blog Jobs Help API Privacy Terms Locations Popular Instagram Lite Meta AI Threads Contact Uploading & Non-Users Meta Verified English Down chevron icon Afrikaans العربية Čeština Dansk Deutsch Ελληνικά English English (UK) Español (España) Español فارسی Suomi Français עברית Bahasa Indonesia Italiano 日本語 한국어 Bahasa Melayu Norsk Nederlands Polski Português (Brasil) Português (Portugal) Русский Svenska ภ
Instagram See everyday moments from your close friends . Log into Instagram Mobile number, username or email Password Log in Forgot password? Log in with Facebook Create new account Meta About Blog Jobs Help API Privacy Terms Locations Popular Instagram Lite Meta AI Threads Contact Uploading & Non-Users Meta Verified English Down chevron icon Afrikaans العربية Čeština Dansk Deutsch Ελληνικά English English (UK) Español (España) Español فارسی Suomi Français עברית Bahasa Indonesia Italiano 日本語 한국어 Bahasa Melayu Norsk Nederlands Polski Português (Brasil) Português (Portugal) Русский Svenska ภ
Facebook Explore the things you love . Log into Facebook Email or mobile number Password Log in Forgot password? Create new account English (US) فارسی العربية Türkçe Deutsch Français (France) Polski More languages… Sign Up Log In Messenger Facebook Lite Video Meta Pay Meta Store Meta Quest Ray-Ban Meta Meta AI Instagram Threads Privacy Policy Privacy Center About Create ad Create Page Developers Careers Cookies Ad choices Terms Help Contact Uploading & Non-Users Meta © 2026
Howard Brooks Appointed to the Immorta Bio Strategic Advisory Board | Medical Device News Magazine LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in, you agree t
Immorta Bio Announces Publication of International Patent Application for SenoVax Home About Us Mission People Careers Science Science of Aging SenoVax™ StemCellRevivify™ Intellectual Property Publications News & Resources News Decks Pipeline Main Pipeline Contact Us About Mission People Careers Contact Science Science of Aging SenoVax™ StemCellRevivify™ Intellectual Property Publications News & Resources News Decks Pipeline Main Pipeline Contact Immorta Bio Announces Publication of International Patent Application for SenoVax PR-Newswire November 25, 2025 Targeting the Root Causes of … Aging as Disease™ , today announced the publication of its international patent application PCT/WO2025184665[1], entitled "Senescence Vaccine." Dr. Thomas Ichim, President and Chief Scientific Officer of Immorta Bio The application describes Immorta Bio's proprietary approach to stimulating the immune system to selectively eliminate senescent cells: the dysfunctional "old cells" that drive aging, inflammation, organ failure, and support tumor growth. … improvement in healthspan These results, along with the publication of this PCT application, strengthen Immorta Bio's position as the only company developing a dual-platform solution to aging that also treats its most lethal diseases. PatentScope.wipo.int ResearchSquare.com Targeteddonc.com Read Full Article Share this post Never Miss A Headline Subscribe to Immorta Bio's Newsletter Thank you! Your submission has been received! Oops! Something went wrong while submi
Instagram See everyday moments from your close friends . Log into Instagram Mobile number, username or email Password Log in Forgot password? Log in with Facebook Create new account Meta About Blog Jobs Help API Privacy Terms Locations Popular Instagram Lite Meta AI Threads Contact Uploading & Non-Users Meta Verified English Down chevron icon Afrikaans العربية Čeština Dansk Deutsch Ελληνικά English English (UK) Español (España) Español فارسی Suomi Français עברית Bahasa Indonesia Italiano 日本語 한국어 Bahasa Melayu Norsk Nederlands Polski Português (Brasil) Português (Portugal) Русский Svenska ภ
Venture Partners, Executives-in-Residence and Advisors Archives - Page 2 of 3 - Pappas Capital Toggle navigation Home About About Us News & Events For Entrepreneurs Contact Us Team Portfolio Ventures Specialized Fund Management About Chiesi Ventures Fund Asia Innovation Ventures AgTech Initiatives Specialized Holdings Translational Medicine About Wake Forest Technology Development Program Tina Wong-Russell Venture Partners, Executives-in-Residence and Advisors Tina Wong-Russell Tina is an Advisor to Pappas Capital and is also a consultant and executive coach to clients … inion Leaders experience garnered the J&J Corporate Standards of Leadership Award. Patrick has frequently been invited to speak on entrepreneurship and company development at the MBA programs at Carnegie Mellon and the University of Pittsburgh Heinz School of Business. Patrick currently serves as an independent director on the board of BioStem Technologies (OTC: BSEM) and on the Executive Board of the Johnny Mac Soldiers Fund, which he founded along with his classmates fr … Soldiers Fund, which he founded along with his classmates from West Point. The fund has raised over $52 million in college scholarships for Gold Star children. Education: United States Military Academy at West Point (BS in Foreign Area Studies) Lisa Dreyer - July 6, 2020 - No Comments Karen LeVert Karen is leading the expansion of the firm’s Specialized Fund Management business with a focus on identifying attractive agricultural technology investment opportunities. She has a … rds including the Council for Entrepreneurial Development’s Outstanding Service Award, induction into the WRAL TechWire Hall of Fame, and the 2022 Women in Agribusiness (WIA) Demeter Award of Excellence. Along with her professional duties Karen serves as a board member for the North Carolina Biotechnology Center, the Economic Development Partnership of North Carolina, the North Carolina Arboretum, AgLaunch, and North Carolina State University College of Agriculture and Life S … ty (BS in Biochemistry and Zoology) Ohio State University (MD) Duke University (Residency) NIH, Heart, Lung and Blood Institute (Post-doctoral fellow, Bethesda) kevinp - June 11, 2013 - No Comments Posts pagination « 1 2 3 » Home About Team Portfolio News & Events Contact Ventures Specialized Funds Translational Medicine © 2026 Pa
Biotechnology Announcements - Bio Newswire Skip to content Menu Recent BioTechnology Stories BioTechnology Announcements About Contact Biotechnology Announcements CUSABIO Transmembrane Proteins: Driving Breakthroughs in Therapeutic Antibody Discovery HOUSTON, Oct. 31, 2024 /PRNewswire/ — In recent years, antibody therapies have seen rapid advancements, becoming pivotal treatments for cancer, infectious diseases, and autoimmune disorders. Innovations such as monoclonal antibodies (mAbs), bispecific antibodies (bsAbs), and American Society of Pharmacovigilance Honors Leaders in Precision M … curity, an Austin company on the cutting edge of ALS Network Announces Research Grant Awarded to AUTTX, LLC. Researchers to accelerate search for ALS therapies LOS ANGELES, Oct. 23, 2024 /PRNewswire/ — The ALS Network, formerly ALS Golden West, has awarded a $125,000 grant through its global research program to AUTTX, LLC. to help RTI Health Solutions and Global Pricing Innovations announce strategic collaboration to provide integrated solutions for drug developers … ustom software development, has been awarded the prestigious Best Place to Work award by Madison Magazine for 2024. The recognition celebrates the company’s Cancer Check Labs Expands into Canada Through Partnership with Healthcode Medical DALLAS, Oct. 17, 2024 /PRNewswire/ — Cancer Check Labs is excited to announce its entry into the Canadian market in partnership with Healthcode Medical, a leader in innovative healthcare solutions. This collaboration aims to enha
Stem Cell Revivify™ Newsletter Home Longevity Diseases of Aging Status Quo Stem Cells Solutions Technologies (ASC, PRC, PPC, pMSC) Therapeutic focus Liver Heart Arteries About Our Mission Team Management Patents Careers News Industry News Bio News Letter News Hot Science Contact About Mission People Careers Contact Science Science of Aging SenoVax™ StemCellRevivify™ Intellectual Property Publications News & Resources News Decks Pipeline Main Pipeline Contact April 3, 2024 Stem Cell Revivify™ Newsletter Category: Science Author's name Boris Reznik, PhD Inour latest newsletter feature,
News Home About Us Mission People Careers Science Science of Aging SenoVax™ StemCellRevivify™ Intellectual Property Publications News & Resources News Decks Pipeline Main Pipeline Contact Us About Mission People Careers Contact Science Science of Aging SenoVax™ StemCellRevivify™ Intellectual Property Publications News & Resources News Decks Pipeline Main Pipeline Contact News and Resources June 9, 2026 Immorta Bio Discusses its AI-Enabled Personalized Therapeutic Paradigm for Restoring Youthful Biology at Leading Global Biotech Forum Read More May 21, 2026 Scientific Longevity Company … ore November 25, 2025 Immorta Bio Announces Publication of International Patent Application for SenoVax Read More October 24, 2025 Immorta Bio's Newest IP + Preclinical Progress: Advancing Mitochondrial Regeneration Strategy Read More October 14, 2025 Immorta Bio’s Research Points to a Potential Pathway Toward "Re-Awakening" Coma Patients Read More September 24, 2025 Immorta Bio Reports Activity of SenoVax™ in CTE Model Read More September 17, 2025 Lung Cancer
Instagram See everyday moments from your close friends . Log into Instagram Mobile number, username or email Password Log in Forgot password? Log in with Facebook Create new account Meta About Blog Jobs Help API Privacy Terms Locations Popular Instagram Lite Meta AI Threads Contact Uploading & Non-Users Meta Verified English Down chevron icon Afrikaans العربية Čeština Dansk Deutsch Ελληνικά English English (UK) Español (España) Español فارسی Suomi Français עברית Bahasa Indonesia Italiano 日本語 한국어 Bahasa Melayu Norsk Nederlands Polski Português (Brasil) Português (Portugal) Русский Svenska ภ
Accera, Inc. Elects Industry Veteran Holger Kunze as CEO and as a Member of the Company's Board of Directors | FirstWord PHARMA You need to enable JavaScript to run this app. Loading...
Our Mission Home About Us Mission People Careers Science Science of Aging SenoVax™ StemCellRevivify™ Intellectual Property Publications News & Resources News Decks Pipeline Main Pipeline Contact Us About Mission People Careers Contact Science Science of Aging SenoVax™ StemCellRevivify™ Intellectual Property Publications News & Resources News Decks Pipeline Main Pipeline Contact Our Mission Treating Diseases Of Aging and Treating Aging As Disease™ At Immorta Bio, our mission is to radically extend healthy human lifespan by targeting the biological root causes of aging and age-related di
Immorta Bio Appoints Howard Brooks to Corporate Board of Directors --> --> LATEST --> LATEST By Country Antigua and Barbuda Argentina Bahamas Barbados Belize Bolivia Brazil Canada Chile Colombia Costa Rica Cuba Dominica Dominican Republic Ecuador El Salvador Grenada Guatemala Guyana Haiti Honduras Jamaica Mexico Nicaragua Panama Paraguay Peru Saint Kitts and Nevis Saint Lucia Saint Vincent and the Grenadines Suriname Trinidad and Tobago United States of America (USA) Uruguay Venezuela New List Your Startup Join Now --> Login Magazines STARTUP NEWS Entrepreneur Stories Industry Insight By count
Instagram See everyday moments from your close friends . Log into Instagram Mobile number, username or email Password Log in Forgot password? Log in with Facebook Create new account Meta About Blog Jobs Help API Privacy Terms Locations Popular Instagram Lite Meta AI Threads Contact Uploading & Non-Users Meta Verified English Down chevron icon Afrikaans العربية Čeština Dansk Deutsch Ελληνικά English English (UK) Español (España) Español فارسی Suomi Français עברית Bahasa Indonesia Italiano 日本語 한국어 Bahasa Melayu Norsk Nederlands Polski Português (Brasil) Português (Portugal) Русский Svenska ภ
Biotechnology Announcements - Bio Newswire Skip to content Menu Recent BioTechnology Stories BioTechnology Announcements About Contact Biotechnology Announcements Sparkling Sciences Obtains International INCI Certification for iPSC Exosome Completes Kyoto University Patent Licensing AgreementTAIPEI, June 23, 2026 /PRNewswire/ — Sparkling Sciences Co., Ltd., under TOMO YUME Group, announced it has obtained international INCI certification for iPSC Exosome and completed Kyoto University’s patent licensing agreement.INCI Scientific Longevity Company Immorta Bio Appoints Former Er … lly defined, universal foundation medium Brain-Body Therapy Pledges $100,000 to Fund Dr. Andrew Sherwood’s Research Project at Duke University Gift deepens the scientific foundation of the app, whose model was informed by Dr. Sherwood’s decades of research on exercise and mental health LOS ANGELES, May 19, 2026 /PRNewswire/ — Brain-Body Therapy, (https://www.brain-bodytherapy.com/), a groundbreaking mental Helio Genomics Announces Strategic Commercial P
%PDF-1.7 %���� 1 0 obj >/Metadata 623 0 R/ViewerPreferences 624 0 R>> endobj 2 0 obj > endobj 3 0 obj >/ExtGState >/XObject >/ProcSet[/PDF/Text/ImageB/ImageC/ImageI] >>/MediaBox[ 0 0 612 792] /Contents 4 0 R/Group >/Tabs/S/StructParents 0>> endobj 4 0 obj > stream x��\Io�8���iPj؊H-����NnLҙ��s� �>�*��]9�o �GR�Dz�h��"����{�D^}^�y��Շ��+��{Y��hZ���spqA�^]�o�'Q�_A�H&^y��fzz��'R����9=y��q�fvzBŠ�P�Y��dIrr�c~���|+�#s���o���| ��_���ӓwb����w . ��G���t��i F9�X2��R�\��^��H0���� ��Q��c�-)�I��1n /�s>���� ^�U@�������|���]����qX����R�7��rV�w�����j(���" ��P�&����^ v��ĄR��� -
Careers Home About Us Mission People Careers Science Science of Aging SenoVax™ StemCellRevivify™ Intellectual Property Publications News & Resources News Decks Pipeline Main Pipeline Contact Us About Mission People Careers Contact Science Science of Aging SenoVax™ StemCellRevivify™ Intellectual Property Publications News & Resources News Decks Pipeline Main Pipeline Contact Careers Become Part of Our Longevity Mission We’re building the future of human health. Join our growing team of scientists, creatives, and innovators reshaping longevity from the inside out. First Name Last Name Em
Careers Home About Us Mission People Careers Science Science of Aging SenoVax™ StemCellRevivify™ Intellectual Property Publications News & Resources News Decks Pipeline Main Pipeline Contact Us About Mission People Careers Contact Science Science of Aging SenoVax™ StemCellRevivify™ Intellectual Property Publications News & Resources News Decks Pipeline Main Pipeline Contact Careers Become Part of Our Longevity Mission We’re building the future of human health. Join our growing team of scientists, creatives, and innovators reshaping longevity from the inside out. First Name Last Name Em
Immorta Bio Appoints Former Ernst & Young Health Sciences Partner Howard Brooks to Strategic Advisory Board | Howard Brooks | 30 comments LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicki
Instagram See everyday moments from your close friends . Log into Instagram Mobile number, username or email Password Log in Forgot password? Log in with Facebook Create new account Meta About Blog Jobs Help API Privacy Terms Locations Popular Instagram Lite Meta AI Threads Contact Uploading & Non-Users Meta Verified English Down chevron icon Afrikaans العربية Čeština Dansk Deutsch Ελληνικά English English (UK) Español (España) Español فارسی Suomi Français עברית Bahasa Indonesia Italiano 日本語 한국어 Bahasa Melayu Norsk Nederlands Polski Português (Brasil) Português (Portugal) Русский Svenska ภ
Immorta Bio Adds Former EY Health Sciences Leader Howard Brooks to Board as Longevity Sector Pushes Toward Clinical and Capital Markets Maturity | citybiz Skip to content citybiz Cities Atlanta Baltimore Boston Charlotte Raleigh Chicago Cleveland Dallas Denver Detroit Global Houston Indianapolis Los Angeles New York Philadelphia Phoenix Pittsburgh Portland San Diego San Francisco Seattle South Florida Washington DC Channels Q&A citybiz+ People Commercial Real Estate General Business Mergers & Acquisitions Financial Services / Investment Firms Venture Capital Internet / Technology Law B
Top 10 Pharma Drug Discovery Delivery Capital Raises and Investors in the U.S. - January 1st - 31st, 2026 -- End of the comment --> Toggle navigation Top Capital Raises CPTV CPGO About Castle Placement Team Testimonials Posts Capital Letters™ A View From The Castle® Data Room Services Capital Raising Castle Referral Program CPGO Competition CPGO I-Bank CPGO Network PE Secondary Transactions Corporate Currency® CPGO Connect New York Asset Management Corp. Call us +212.418.1180 [email protected] Top 10 Pharma Drug Discovery Delivery Capital Raise
Tietosuojavalintasi guce guce Tietosuojasi on meille tärkeää Tietosuojavalintojasi käytetään kaikissa Yahoo-konsernin tarjoamissa sivustoissa ja sovelluksissa. Yahoo käyttää evästekäytännöstämme ."> Evästeet Evästeiden (sekä vastaavien tekniikoiden, esimerkiksi verkkotallennuksen) avulla verkkosivustojen sovellusten ylläpitäjät voivat tallentaa ja lukea laitteesi tietoja. Lue lisää evästekäytännöstämme . evästeitä seuraaviin tarkoituksiin: tarjotaksemme sivustomme ja sovelluksemme sinulle todentaaksemme käyttäjät, estääksemme roskapostia ja väärinkäytöksiä sekä toteuttaaksemme tietoturvatoimia
Dr. Russel Kaufman, Renowned Medical Innovator and Business Leader, Joins Immorta Bio's Board of Directors Home About Us Mission People Careers Science Science of Aging SenoVax™ StemCellRevivify™ Intellectual Property Publications News & Resources News Decks Pipeline Main Pipeline Contact Us About Mission People Careers Contact Science Science of Aging SenoVax™ StemCellRevivify™ Intellectual Property Publications News & Resources News Decks Pipeline Main Pipeline Contact Dr. Russel Kaufman, Renowned Medical Innovator and Business Leader, Joins Immorta Bio's Board of Directors
PR Toolkit - Small Business News Releases Send a News Release Blog For Journalists PR Toolkit Home PR Learning Center Reach the Media Request Information Home PR Learning Center Reach the Media Request Information Search Advanced Search Small Business Articles Tips and Advice Case Studies Diagrams & Templates Small Business News Releases Save more than $2.000 in free and discounted services from PR Newswire! Small Business News Releases Search Contact PR Newswire 888-776-0942 from 8 AM - 10 PM ET Chat Online with an Expert Contact Us General Inquiries Request a Demo Editorial Bureaus Pa
Immorta Bio's Anti-Aging Breakthrough Extends Lifespan by 73% | Mihir Kampani posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign i … phase, shifting from long-standing scientific promise toward practical clinical application. BioRestorative Therapies, Inc. is at the forefront of this transition, advancing stem cell-based therapies for high-need conditions such as degenerative disc disease while building a complementary commercial platform in bio-cosmeceuticals. In this conversation with BioPharma BoardRoom , CEO Lance Alstodt outlines how the company is overcoming key barriers in clinical translation, diff … ingle-stranded RNA Enables high-efficiency, footprint-free reprogramming Proven Application: Repeated transfection of Sox2 mRNA, along with Oct4, Klf4, Lin-28, and c-Myc, has been successfully used to reprogram human fibroblasts into iPSCs. From disease modeling to regenerative therapies, mRNA-based reprogramming offers a safer, integration-free alternative for stem cell generation. To Know More: 📩 𝗶𝗻𝗳𝗼@𝗿𝗲𝗽𝗿𝗼𝗰𝗲𝗹𝗹.𝗰𝗼𝗺 #StemCells #iPSC #CellReprogramming #Regen … ety than ever before. Why this is a strategic win for industry partners: ✅Broad Application from genetic disorders to post-chemotherapy recovery. ✅ Eliminates the storage and processing hurdles of donor-derived blood products. ✅ Dramatically lowers the quantity of stem cells required for transplants, reducing both patient risk and hospital costs. ✅A sustainable, scalable solution for trauma care, chemotherapy recovery, and military field medicine. This isn't just a treatment;
Oncothyreon Inc. - Drug pipelines, Patents, Clinical trials - Synapse Products Data Feature Plans Request Demo Sign Up for Free Last update 14 Aug 2025 Oncothyreon Inc. Private Company | 1985 | Kentucky, United States | 10-50 | www.oncothyreon.com Private Company | 1985 | Kentucky, United States | 10-50 | www.oncothyreon.com Last update 14 Aug 2025 Overview Pipeline Deal Translational Medicine Profit Grant & Funding(NIH) Investment Financing Overview Related 100 Clinical Results associated with Oncothyreon Inc. Login to view more data 0 Patents (Medical) associated with Oncothyreon Inc. Lo … practicing oncologist at The Everett Clinic and completed a hematology oncology fellowship at Oregon Health & Science University after completing his residency there in internal medicine. He holds an M.D. from the University of Oklahoma’s College of Medicine. “I am incredibly excited to join Umoja as Chief Medical Officer at such an important time for both the company and the in vivo CAR T cell therapy field. Two of Umoja’s VivoVec in vivo CAR T cell therapy programs are open … ne months of 2023, including $233 million in the third quarter. Apnimed’s prize possession is an oral pill to treat sleep apnea, upending a market that’s largely dominated by CPAP machines and devices. That med, AD109, is currently in the middle of its phase 3 program with data expected in the first half of 2025 and an NDA expected shortly after, assuming the data are positive. In an interview with Fierce Biotech, Goodrich says he’s often gravitated toward working on tr … entide Asset Management, where he co-managed their Healthcare and Life Sciences Fund and developed an understanding of the Company and the potential of azenosertib in ovarian cancer and other tumors. We believe Kyle’s experience as a biotechnology portfolio manager, with a background in scientific research, will help us drive the Company’s growth and value creation.” Dr. Hausman is an oncologist with extensive experience in all aspects of drug development and clinical strateg … itions of over 360K organizations with Synapse. login or view full example data Grant & Funding(NIH) Access more than 2 million grant and funding information to elevate your research journey. login or view full example data Investment Gain insights on the latest company investments from start-ups to established corporations. login or view ful
Skip to main content MedPath Trial Home Trials Products Organizations News Research Pricing Search 中 Login Data Sources: ClinicalTrials.gov EU CTR FDA EMA NMPA TGA Health Canada WHO ICTRP MedPath Trial Home Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research. Product Clinical Trials Drug Intelligence Global Approvals AI Research Pricing Resources FAQ Search Company News About Contact Legal Privacy Policy Terms of Service Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medica
FDA Accepts sBLA Filing of Leqembi® (lecanemab-irmb) for IV Maintenance Dosing in Early Alzheimer's Treatment × Search your requirement Search your requirement Home Press Releases Submit Release Events Reach Us Social media Search Home Press Releases Submit Release Events Reach Us Search FDA Accepts sBLA Filing of Leqembi® (lecanemab-irmb) for IV Maintenance Dosing in Early Alzheimer's Treatment Details By BioArctic BioArctic Jun 09 BioArctic AB's partner Eisai announced today that that the U.S. Food and Drug Administration (FDA) has accepted Eisai's Supplemental Biologics License Applica … ents and care partners to continue long-term. Additionally, Eisai initiated the rolling submission of a BLA to the FDA for the Leqembi subcutaneous autoinjector for weekly maintenance dosing after it was granted Fast Track designation by the FDA in May 2024. Leqembi is now approved in the U.S., Japan, China and South Korea, and applications have been submitted for review in several countries including the European Union, Australia, Brazil, Canada, Hong Kong, Great Britain, In … aceutical PressWire® Pharmaceutical EventsWire® Please enable the javascript to submit this form Subscribe Most Popular Results from Incyte’s Phase 3 frontMIND Trial of Tafasitamab Combination Show Prolonged Progression-Free Survival Presented at EHA 2026 By Incyte Jun 15 Fzata secures a clinical trial agreement for FZ002, targeting C. difficile treatment. By Fzata, Inc. Mar 12 Neurizon Begins Dosing of NUZ-001 in HEALEY ALS Platform Trial By Neurizon Therapeutics Limited Feb … nditions × and the Privacy policy × Please enable the javascript to submit this form Subscribe © Pharmaceutical Era — A product of HISSM. All Rights Reserved. This site uses cookies. By continuing to browse the site, you are agreeing to our use of cookies. To find out more, please click here . I understand
Immunotherapy Success Reinforces Immorta's Innovative Cancer Treatment Strategy Home About Us Mission People Careers Science Science of Aging SenoVax™ StemCellRevivify™ Intellectual Property Publications News & Resources News Decks Pipeline Main Pipeline Contact Us About Mission People Careers Contact Science Science of Aging SenoVax™ StemCellRevivify™ Intellectual Property Publications News & Resources News Decks Pipeline Main Pipeline Contact Immunotherapy Success Reinforces Immorta's Innovative Cancer Treatment Strategy August 13, 2024 In today’s issue: · Immorta Patents , … reby exhibiting superior tissue and organ rejuvenation capabilities. The patent application includes data demonstrating that Immorta’s pMSC product reduces liver failure by stimulating Regulatory T Cells. The ability of pMSC to generate these cells was found to be dependent on the cytokine interleukin-35 (IL-35). Notably, pMSC was shown to produce IL-35 at substantially higher levels compared to other mesenchymal stem cell types. The patent also encompasses various methods fo
All Clinical Trials & Medical Discoveries News and Press Releases from PR Newswire Accessibility Statement Skip Navigation Resources Investor Relations Journalists Agencies Client Login Send a Release News Products Contact Search Search When typing in this field, a list of search results will appear and be automatically updated as you type. Searching for your content... No results found. Please change your search terms and try again. News in Focus Browse News Releases All News Releases All Public Company English-only News Releases Overview Multimedia Gallery All Multimedia All Photos All V … Dallas nonprofit... Feb 18, 2026, 14:30 ET Hansa Biopharma's Biologics License Application (BLA) for imlifidase accepted by the FDA Hansa Biopharma AB, ("Hansa" or "the Company"), (Nasdaq Stockholm: HNSA), today announced that its Biologics License Application (BLA) for imlifidase ... Feb 18, 2026, 14:28 ET Hansa Biopharma's Biologics License Application (BLA) for imlifidase accepted by the FDA Hansa Biopharma AB, ("Hansa" or "the Company&q … ny"), (Nasdaq Stockholm: HNSA), today announced that its Biologics License Application (BLA) for imlifidase ... Feb 18, 2026, 13:03 ET Belay Diagnostics Announces the Validation of Summit™ 2.0 Comprehensive Genomic Profile Assay in Cerebrospinal Fluid (CSF) Belay Diagnostics, an innovative CLIA/CAP accredited laboratory focused on the development and commercialization of molecular diagnostics targeting... Feb 18, 2026, 11:14 ET Cancer Stress Protein Helps Tumors Hide Fro … older adults with dementia has... Feb 17, 2026, 08:00 ET Andelyn Biosciences to Apply the AAV Curator® Platform to Manufacture Clinical Grade AAV for Drake Rayden Foundation for the Treatment of Nonketotic Hyperglycinemia Andelyn Biosciences, Inc., a leading and patient-focused cell and gene therapy Contract Development and Manufacturing Organization (CDMO), has been... Feb 17, 2026, 07:45 ET TuHURA Files Investigational New Drug Application for TBS-2025 in the Treatment of B … monstrating the... Feb 15, 2026, 19:10 ET CStone Announces FDA Clearance of IND Application for Its Novel Trispecific Antibody CS2009 (PD-1/VEGF/CTLA-4) to Advance into Phase II Clinical Trial CStone Pharmaceuticals ("CStone," HKEX: 2616), an innovation-driven biopharmaceutical company focused on the research and development of therapie
Senolytic Therapy Market Research Report 2034 Report Store Aerospace & Defense Automotive & Logistics Banking, Financial Services & Insurance Construction & Manufacturing Consumer Goods Energy & Power Food & Beverage Healthcare ICT, Semiconductor & Electronics Materials & Chemicals Trending --> Press-Release Blog --> About Us Our Team FAQs Contact Us Search Search reports. Senolytic Therapy Market Research Report 2034 Get free sample report Request for Customiztion Buy Now Home Healthcare Healthcare & Pharmaceuticals Senolytic Therapy Market Research Report 2034 Senolytic Therapy Market Resear … ening a new frontier in targeted senolytic drug delivery. Concurrently, topical application of ABT-263 demonstrated an 80% wound healing rate in treated aged mice versus 56% in controls by day 24, underscoring senolytic therapy's potential beyond systemic conditions. The emergence of next-generation modalities - including CAR-T senolytic platforms and senolytic vaccines such as Immorta Bio's SenoVax (patent filed November 2025) - suggests that the pipeline is diversifying wel … cells outright, accounted for approximately 17.6% share and are finding growing application in patients for whom acute senescent cell elimination carries toxicity risks. CAR-T Based Senolytics , while currently at the earliest commercial stage at approximately 8.0% share, represent the highest-growth potential segment, projected at a CAGR exceeding 28% through 2034 as early-phase trials for uPAR-targeting CAR-T constructs generate data and the manufacturing cost curve for per … the acromegaly treatment market , where targeted hormonal therapies are finding application across a range of pituitary disorders. From a competitive and strategic standpoint, the emerging integration of senolytic therapy with precision longevity medicine platforms - combining genetic aging clocks, epigenetic biomarker testing, metabolomic profiling, and senolytic interventions - is creating a high-margin, premium healthcare services market estimated to be worth over $3 billi … cine - Researchers published findings in the journal Aging showing that topical application of the senolytic drug ABT-263 reduced senescent cell burden in aged mouse skin and significantly improved subsequent wound healing speed, with 80% of treated mice fully healed by day 24 versus 56% of controls. April 2026 Thomas Jefferson University - Resea
Senovax™: cutting-edge immunotherapy for lung cancer Home About Us Mission People Careers Science Science of Aging SenoVax™ StemCellRevivify™ Intellectual Property Publications News & Resources News Decks Pipeline Main Pipeline Contact Us About Mission People Careers Contact Science Science of Aging SenoVax™ StemCellRevivify™ Intellectual Property Publications News & Resources News Decks Pipeline Main Pipeline Contact Senovax™: cutting-edge immunotherapy for lung cancer June 12, 2024 Malignant tumors have a notorious ability to shield themselves from the many things that doctors and sc … preclinical development and plans to file for an Investigational New Drug (IND) application soon, aiming to initiate clinical trials for advanced lung cancer patients. The company is committed to treating age-related diseases and leveraging SenoVax™ in enhancing the body's intrinsic senescent cell clearance processes. Application of SenoVax™ to cancer treatment can not only potentially prove to become an effective oncologic therapeutic, but also has been demonstrating it
Surprising longevity boosters: top medications revealed Home About Us Mission People Careers Science Science of Aging SenoVax™ StemCellRevivify™ Intellectual Property Publications News & Resources News Decks Pipeline Main Pipeline Contact Us About Mission People Careers Contact Science Science of Aging SenoVax™ StemCellRevivify™ Intellectual Property Publications News & Resources News Decks Pipeline Main Pipeline Contact Surprising longevity boosters: top medications revealed March 26, 2024 You might have been increasing your lifespan without even knowing it. Have you been taking Viagr … foundational ones, as their Personalized Progenitor Cell (PPC) platform, patent application #63/599440. Term of the Day What is Scientific Longevity? We call Scientific Longevity science-based and regulatory proven research and development of therapeutics that extend lives while improving health. Boris Reznik, PhD Chairman Read Full Article Share this post Never Miss A Headline Subscribe to Immorta Bio's Newsletter Thank you! Your submission has been received! Oop
Instagram See everyday moments from your close friends . Log into Instagram Mobile number, username or email Password Log in Forgot password? Log in with Facebook Create new account Meta About Blog Jobs Help API Privacy Terms Locations Popular Instagram Lite Meta AI Threads Contact Uploading & Non-Users Meta Verified English Down chevron icon Afrikaans العربية Čeština Dansk Deutsch Ελληνικά English English (UK) Español (España) Español فارسی Suomi Français עברית Bahasa Indonesia Italiano 日本語 한국어 Bahasa Melayu Norsk Nederlands Polski Português (Brasil) Português (Portugal) Русский Svenska ภ
Publications Home About Us Mission People Careers Science Science of Aging SenoVax™ StemCellRevivify™ Intellectual Property Publications News & Resources News Decks Pipeline Main Pipeline Contact Us About Mission People Careers Contact Science Science of Aging SenoVax™ StemCellRevivify™ Intellectual Property Publications News & Resources News Decks Pipeline Main Pipeline Contact Publications Mesenchymal Stem Cells For Rheumatoid Arthritis Can Senolysis Be Used To Overcome Tumor Immune Evasion? Never Miss A Headline Subscribe to Immorta Bio's Newsletter Thank you! Your submission h
JavaScript is disabled In order to continue, we need to verify that you're not a robot. This requires JavaScript. Enable JavaScript and then reload the page.
Pipeline Home About Us Mission People Careers Science Science of Aging SenoVax™ StemCellRevivify™ Intellectual Property Publications News & Resources News Decks Pipeline Main Pipeline Contact Us About Mission People Careers Contact Science Science of Aging SenoVax™ StemCellRevivify™ Intellectual Property Publications News & Resources News Decks Pipeline Main Pipeline Contact Clinical Development Pipeline Immorta Bio's longevity focused pipeline encompasses our two platforms; SenoVax™ and StemCell Revivify™ and their unique placement in various high unmet need indications Never Mis
Immorta Bio Files Patent for Senolytic Vaccine SenoVax | Ruchi Verma posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in, you agree … y biotech Immorta Bio has announced the publication of its international patent application for SenoVax, a first-in-class senolytic immunotherapy designed to eliminate senescent cells, the dysfunctional “old cells” that accumulate with age and drive chronic disease. https://lnkd.in/gcDn7JsU #Drug #Patent #Pharma #Vaccine Ishita Rustagi Satish Kumar Roop Singh Chauhan Effectual Services 32 Like Comment Share Copy LinkedIn Facebook X To view or add a comment, sign in More Relev … udy completed to support the filing, EU patent granted, and recent financing to fund manufacturing and launch prep. Estimated market size around $700M per year. ⚛️ Why it matters: • Near-term regulatory catalyst with defined milestones • Focus on an underserved patient segment • Strengthened IP and clear U.S./EU pathways • Multiple upcoming catalysts in 2H 2025 and 2026 ▶️ Watch the 30-second overview: https://bit.ly/45v11YT PharmaVoice Genetic Engineering & Biotechnology … udy completed to support the filing, EU patent granted, and recent financing to fund manufacturing and launch prep. Estimated market size around $700M per year. ⚛️ Why it matters: • Near-term regulatory catalyst with defined milestones • Focus on an underserved patient segment • Strengthened IP and clear U.S./EU pathways • Multiple upcoming catalysts in 2H 2025 and 2026 ▶️ Watch the 30-second overview: https://bit.ly/45v11YT PharmaVoice Genetic Engineering & Biotechnology … udy completed to support the filing, EU patent granted, and recent financing to fund manufacturing and launch prep. Estimated market size around $700M per year. ⚛️ Why it matters: • Near-term regulatory catalyst with defined milestones • Focus on an underserved patient segment • Strengthened IP and clear U.S./EU pathways • Multiple upcoming catal
Treating Diseases of Aging and Treating Aging As Disease™ Treating Diseases of Aging Home About Us Mission People Careers Science Science of Aging SenoVax™ StemCellRevivify™ Intellectual Property Publications News & Resources News Decks Pipeline Main Pipeline Contact Us About Mission People Careers Contact Science Science of Aging SenoVax™ StemCellRevivify™ Intellectual Property Publications News & Resources News Decks Pipeline Main Pipeline Contact OUR MISSION: REVERSE AGING ELIMINATE CANCER REJUVENATE ORGANS TREATING DISEASES OF AGING AND TREATING AGING AS DISEASE™ Latest News June 9
Instagram See everyday moments from your close friends . Log into Instagram Mobile number, username or email Password Log in Forgot password? Log in with Facebook Create new account Meta About Blog Jobs Help API Privacy Terms Locations Popular Instagram Lite Meta AI Threads Contact Uploading & Non-Users Meta Verified English Down chevron icon Afrikaans العربية Čeština Dansk Deutsch Ελληνικά English English (UK) Español (España) Español فارسی Suomi Français עברית Bahasa Indonesia Italiano 日本語 한국어 Bahasa Melayu Norsk Nederlands Polski Português (Brasil) Português (Portugal) Русский Svenska ภ
All Banking & Financial Services News and Press Releases from PR Newswire Accessibility Statement Skip Navigation Resources Investor Relations Journalists Agencies Client Login Send a Release News Products Contact Search Search When typing in this field, a list of search results will appear and be automatically updated as you type. Searching for your content... No results found. Please change your search terms and try again. News in Focus Browse News Releases All News Releases All Public Company English-only News Releases Overview Multimedia Gallery All Multimedia All Photos All Videos Mul … the various national MiCAR transition periods approach their final 1 July 2026 deadline, Bybit EU is launching its "Move Your Funds, Get Rewarded" ... Jun 22, 2026, 11:55 ET /C O R R E C T I O N -- National Association of Personal Financial Advisors (NAPFA)/ The National Association of Personal Financial Advisors (NAPFA) today introduced a new Fiduciary Standard that raises the bar for excellence in... Jun 22, 2026, 11:51 ET In HelloNation, Wealth Advisor Matt Cupl … the various national MiCAR transition periods approach their final 1 July 2026 deadline, Bybit EU is launching its "Move Your Funds, Get Rewarded" ... Jun 22, 2026, 11:44 ET Simulations Plus (SLP) Investigation: Investors Who Suffered Losses Encouraged to Contact Johnson Fistel Johnson Fistel, PLLP is investigating potential securities law violations on behalf of investors of Simulations Plus, Inc. (NASDAQ: SLP). The... Jun 22, 2026, 11:35 ET Shareholder Alert: Ade … T U.S. Securities and Exchange Commission Establishes Elanco Animal Health Fair Fund UNITED STATES OF AMERICA Before the SECURITIES AND EXCHANGE COMMISSION ADMINISTRATIVE PROCEEDING File No. 3-22309 In the Matter of Elanco Animal... Jun 22, 2026, 09:00 ET GROUPAUTO International übernimmt vollständiges Eigentum an Softeca und beschleunigt damit die digitale Transformation im Automobil-Ersatzteilmarkt GROUPAUTO International (GAI) gab heute die Übernahme der restlichen Anteile … , 08:00 ET U.S. Securities and Exchange Commission Establishes FirstEnergy Fair Fund UNITED STATES OF AMERICA Before the SECURITIES AND EXCHANGE COMMISSION ADMINISTRATIVE PROCEEDING File No. 3-22111 In the Matter of FirstEnergy Corp., ... Jun 22, 2026, 07:50 ET CH4 Natural Solutions Corporation Announces the Separate Trading of its Class A Ordina
Instagram See everyday moments from your close friends . Log into Instagram Mobile number, username or email Password Log in Forgot password? Log in with Facebook Create new account Meta About Blog Jobs Help API Privacy Terms Locations Popular Instagram Lite Meta AI Threads Contact Uploading & Non-Users Meta Verified English Down chevron icon Afrikaans العربية Čeština Dansk Deutsch Ελληνικά English English (UK) Español (España) Español فارسی Suomi Français עברית Bahasa Indonesia Italiano 日本語 한국어 Bahasa Melayu Norsk Nederlands Polski Português (Brasil) Português (Portugal) Русский Svenska ภ
Tietosuojavalintasi guce guce Tietosuojasi on meille tärkeää Tietosuojavalintojasi käytetään kaikissa Yahoo-konsernin tarjoamissa sivustoissa ja sovelluksissa. Yahoo käyttää evästekäytännöstämme ."> Evästeet Evästeiden (sekä vastaavien tekniikoiden, esimerkiksi verkkotallennuksen) avulla verkkosivustojen sovellusten ylläpitäjät voivat tallentaa ja lukea laitteesi tietoja. Lue lisää evästekäytännöstämme . evästeitä seuraaviin tarkoituksiin: tarjotaksemme sivustomme ja sovelluksemme sinulle todentaaksemme käyttäjät, estääksemme roskapostia ja väärinkäytöksiä sekä toteuttaaksemme tietoturvatoimia
Empowered Patient Podcast: Driving Longevity and Treating Diseases of Aging Using Cellular Rejuvenation with Boris Reznik Immorta Bio TRANSCRIPT | Karen Jagoda LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join
Empowered Patient Podcast: Driving Longevity and Treating Diseases of Aging Using Cellular Rejuvenation with Boris Reznik Immorta Bio Toggle navigation About Contact Episodes All Episodes Categories Addiction Aging and Seniors Allergies Big Data Big Data and AI Cancer Cardiology CBD Cell Therapy Central Nervous System Clinical AI Clinical Trials COVID-19 Depression Dermatology Diabetes Diagnostics Dietary Supplements Digital Health Doctors Empowering Patients Epigenetics Gastrointestinal Disorders general Gene Therapy Genetics GIS Healthcare Investing Healthcare Protesting Healthcare workers H … ith Karen Jagoda is a window into the latest innovations in digital health, the application of AI for administrative and clinical uses, the changing dynamic between doctors and patients, personalized medicine, cell and gene therapies, aging in place, wearables and sensors, clinical trials and advances in clinical research, payer trends, transparency in the medical marketplace and challenges for connected health entrepreneurs. This show continues to evolve driven by the conver
News Home About Us Mission People Careers Science Science of Aging SenoVax™ StemCellRevivify™ Intellectual Property Publications News & Resources News Decks Pipeline Main Pipeline Contact Us About Mission People Careers Contact Science Science of Aging SenoVax™ StemCellRevivify™ Intellectual Property Publications News & Resources News Decks Pipeline Main Pipeline Contact News and Resources January 28, 2025 The Trick With Senolytics Read More January 10, 2025 Immorta Bio to Present New Data on SenoVax™ and StemCell Revivify™ at Biotech Showcase 2025 Read More December 18, 2024 Immorta B … of Directors Read More July 26, 2024 Immorta Bio Files Investigational New Drug Application for First in Class Senolytic Immunotherapy SenoVax™ for Treatment of Advanced Lung Cancer Read More June 12, 2024 Immorta Bio Reports Successful Inhibition of Lung Cancer Growth by Senolytic Immunotherapy Product SenoVax™ Read More June 12, 2024 Senovax™: cutting-edge immunotherapy for lung cancer Read More May 24, 2024 Pmsc-11: pioneering liver failure treatment with stem cells Read M
Featured on The Bio Report Podcast - Targeting Senescent Cells Home About Us Mission People Careers Science Science of Aging SenoVax™ StemCellRevivify™ Intellectual Property Publications News & Resources News Decks Pipeline Main Pipeline Contact Us About Mission People Careers Contact Science Science of Aging SenoVax™ StemCellRevivify™ Intellectual Property Publications News & Resources News Decks Pipeline Main Pipeline Contact Featured on The Bio Report Podcast - Targeting Senescent Cells October 21, 2024 Targeting Senescent Cells to Treat Aging-Related Diseases with Dr. Thomas Ichim … cells and cancer 10:00 – 15:56 Immorta’s approach to cell therapy 16:10 – 19:00 Application of treatment 19:17 – 21:20 Pipeline 21:37 – 26:07 SenoVax™ discussion 26:20 – 32:09 Immorta’s forward missions and goals Full Podcast: The Bio Report Follow Immorta Bio LinkedIn X Read Full Article Share this post Never Miss A Headline Subscribe to Immorta Bio's Newsletter Thank you! Your submission has been received! Oops! Something went wrong while submitting the form. B
Immorta Bio CEO Featured in Empowered Patient Podcast Home About Us Mission People Careers Science Science of Aging SenoVax™ StemCellRevivify™ Intellectual Property Publications News & Resources News Decks Pipeline Main Pipeline Contact Us About Mission People Careers Contact Science Science of Aging SenoVax™ StemCellRevivify™ Intellectual Property Publications News & Resources News Decks Pipeline Main Pipeline Contact Immorta Bio CEO Featured in Empowered Patient Podcast October 17, 2024 Driving Longevity and Treating Diseases of Aging Using Cellular Rejuvenation with Dr. Boris Reznik
Immorta Bio, Inc. - Drug pipelines, Patents, Clinical trials - Synapse Products Data Feature Plans Request Demo Sign Up for Free Last update 08 May 2025 Immorta Bio, Inc. Private Company | 2023 | Florida, United States | < 10 | www.immortabio.com Private Company | 2023 | Florida, United States | < 10 | www.immortabio.com Last update 08 May 2025 Overview Pipeline Deal Translational Medicine Profit Grant & Funding(NIH) Investment Financing Overview Tags Neoplasms Digestive System Disorders Cardiovascular Diseases Stem cell therapy Cell therapy Mesenchymal stem cell therapy Disease doma … ication Non-Small Cell Lung Cancer Inactive Indication - Drug Highest Phase IND Application First Approval Ctry. / Loc. - First Approval Date - SNVG-34 Target - Mechanism - Active Org. Immorta Bio, Inc. Originator Org. Immorta Bio, Inc. Active Indication Breast Cancer Inactive Indication - Drug Highest Phase Preclinical First Approval Ctry. / Loc. - First Approval Date - PMSC-11 Target - Mechanism - Active Org. Immorta Bio, Inc. Originator Org. Immorta Bio, Inc. Active Indica … ase 2, and phase 2/3 is incorporated into phase 3 Discovery 3 6 Preclinical IND Application 1 Login to view more data Current Projects Drug(Targets) Indications Global Highest Phase SenoVax Non-Small Cell Lung Cancer More IND Application SNVP-32 Pancreatic Cancer More Preclinical PMSC-12 Sepsis More Preclinical PPCA-03 Limb ischemia More Preclinical PMSC-11 liver function failure More Preclinical Login to view more data Deal Boost your decision using our deal data. login or v … itions of over 360K organizations with Synapse. login or view full example data Grant & Funding(NIH) Access more than 2 million grant and funding information to elevate your research journey. login or view full example data Investment Gain insights on the latest company investments from start-ups to established corporations. login or view full example data Financing Unearth financing trends to validate and advance investment opportunities. login or view full example data
Treating Diseases of Aging Treating Diseases of Aging Home Technologies Aging as Disease Stem Cells Solutions Technologies Pipeline ImmortaBio therapeutics pipeline Liver Failure Lung cancer About Us Our Mission Management Team Patents Collaboration Opportunities Careers News and Resources Industry News Bio News Letter News and Resources Hot Science Contact Us Technologies Overview Platforms STEM CELL REVIVIFY™ Pipeline About Us Our Mission Management Team Patents Collaboration Opportunities Careers Contact Us News and Resources Industry News Bio News Letter News and Resources Science Contact
Immorta Bio, a Scientific Longevity Company, Appoints Pharmaceutical Industry Veteran Dr. Armin Rath as Chief Business Officer Accessibility Statement Skip Navigation Resources Investor Relations Journalists Agencies Client Login Send a Release News Products Contact Search Search When typing in this field, a list of search results will appear and be automatically updated as you type. Searching for your content... No results found. Please change your search terms and try again. News in Focus Browse News Releases All News Releases All Public Company English-only News Releases Overview Multimedia … tform Login ProfNet Data Privacy Do not sell or share my personal information : Submit via [email protected] Call Privacy toll-free: 877-297-8921 Contact PR Newswire Products About My Services All News Releases Platform Login ProfNet Call PR Newswire at 888-776-0942 Terms of Use Privacy Policy Information Security Policy Site Map RSS Cookies Copyright © 2026 Cision US Inc. --> -->
Management Team Home About Us Mission People Careers Science Science of Aging SenoVax™ StemCellRevivify™ Intellectual Property Publications News & Resources News Decks Pipeline Main Pipeline Contact Us About Mission People Careers Contact Science Science of Aging SenoVax™ StemCellRevivify™ Intellectual Property Publications News & Resources News Decks Pipeline Main Pipeline Contact Management Close (X) Boris Reznik During his career spanning four decades, Dr. Reznik founded and built technology companies into market leaders, managed multiple INC. 500 companies, and led multiple program
Immorta Bio Announces Personalized Progenitor Cell Platform for Organ Specific Regeneration - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene The … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Immorta Bio Announces Personalized Progenitor Cell Platform for Organ Specific Regeneration January 2, 2024 | 2 min read Twitter LinkedIn Facebook Email Print Immorta Bio, Inc. announced today its Personalized Progenitor Cell (PPC) platform and filing of associated intellectual property. Unique Tissue Creating Ce … In addition to proprietary know-how and trade secrets, the company filed patent application #63/599440. Through leveraging organ-specific molecules and "injury signals," the patent application teaches efficient means of transforming immortalized Personalized Regenerative Cells into cells that can directly restore and rejuvenate damaged or aged organs and tissues. "One of the limitations of commonly used stem cell therapies is their reliance on in vivo differentiation," said T … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Immorta Bio Reports Successful Inhibition of Lung Cancer Growth by Senolytic Immunotherapy Product SenoVax™ - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends C … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Immorta Bio Reports Successful Inhibition of Lung Cancer Growth by Senolytic Immunotherapy Product SenoVax™ June 12, 2024 | 3 min read Twitter LinkedIn Facebook Email Print Immorta Bio Inc, a science-based Life Extension company announced today positive preclinical findings utilizing its senescent cell-killing immunothe … of preclinical development and plans to file an Investigational New Drug (IND) application with the FDA shortly to initiate treatment of advanced lung cancer patients. "Immorta Bio is a Scientific Longevity Company. In that regard we are developing two longevity therapeutics platforms: Cellular Rejuvenation and Senolytic Immunotherapy (SenoVax™)," said Dr. Boris Reznik , Chairman and CEO of Immorta Bio. "The results disclosed today are part of our second technology platform, … ystem's natural tendency to 'clean up' dysfunctional and senescent cells. Application of SenoVax™ to cancer treatment not only can potentially produce some effective oncology drug, but also is proving its potency in Senolytic life extension applications." About Immorta Bio: Immorta Bio is a science-based longevity biotechnology company developing efficient and practical personalized stem cell platforms aimed at Treating Diseases of Aging and Treating Aging as Disease™. … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Venvalo Group Launches Immorta Bio, Inc Aimed at Providing Unlimited Personalized Cells for Treating Diseases of Aging and Treating Aging as Disease™ - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Venvalo Group Launches Immorta Bio, Inc Aimed at Providing Unlimited Personalized Cells for Treating Diseases of Aging and Treating Aging as Disease™ December 6, 2023 | 2 min read Twitter LinkedIn Facebook Email Print Venvalo Group announced today formation of Immorta Bio, Inc, a regenerative medicine company dedicated … when you subscribe to GenePool! MORE ON THIS TOPIC Podcast AbbVie keeps M&A rolling, FDA’s reversal train chugs along, BIO 2026 dispatch, more June 24, 2026 · 1 min read · Jef Akst BioSpace at BIO to find out" href="https://www.biospace.com/drug-development/can-adcs-be-kinder-and-gentler-join-biospace-at-bio-to-find-out" > Antibody-drug conjugate Can ADCs be kinder and gentler? Join BioSpace at BIO to find out June 23, 2026 ·&n … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Immorta Bio Welcomes Dr. Vlad Bykoriz as its Chief Medical Officer - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Pres … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search News Business Immorta Bio Welcomes Dr. Vlad Bykoriz as its Chief Medical Officer January 23, 2024 | 2 min read Twitter LinkedIn Facebook Email Print Immorta Bio, Inc. announced today that Vlad Bykoriz, MD, PhD, has joined the company’s management team. After over 20 years with Pfizer and Abbott, Dr. … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Immorta Bio Inc, a Longevity Company, Announces a Significant Breakthrough in Treatment of Liver Failure - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Immorta Bio Inc, a Longevity Company, Announces a Significant Breakthrough in Treatment of Liver Failure May 23, 2024 | 3 min read Twitter LinkedIn Facebook Email Print Immorta Bio Inc, a science-based Life Extension company has announced patent filing on successful treatment of the carbon tetrachloride model of liver f … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Immorta CSO Featured in BioFuture 2024 Longevity Panel Home About Us Mission People Careers Science Science of Aging SenoVax™ StemCellRevivify™ Intellectual Property Publications News & Resources News Decks Pipeline Main Pipeline Contact Us About Mission People Careers Contact Science Science of Aging SenoVax™ StemCellRevivify™ Intellectual Property Publications News & Resources News Decks Pipeline Main Pipeline Contact Immorta CSO Featured in BioFuture 2024 Longevity Panel November 3, 2024 Immorta Bio is excited to share that our President and Chief Scientific Officer, Dr. Thomas Ichi
Partnering Companies - BIO International Convention 2026 Start your engines! BIO 2026 is June 22-25 at the San Diego Convention Center. Program announced! See the 130+ sessions in 18 focus areas. Generate Your Personal Event Schedule in Seconds! GENERATE NOW Start your engines! BIO 2026 is June 22-25 at the San Diego Convention Center. Program announced! See the 130+ sessions in 18 focus areas. Generate Your Personal Event Schedule in Seconds! GENERATE NOW June 22-25 | San Diego Event Info Event Overview About BIO International Convention Future dates Attendee Policies Schedule at a Gla … ific Progress AI Implementation Biomanufacturing Academia Company Presentations Apply for a Company Presentation 2026 Presenting Companies Curated Programs AI Summit BIO Storytelling Stage BioProcess Theater Global Innovation Hubs Professional Development Courses Start-Up Stadium Student Program BIO Partnering™ BIO Partnering™ at BIO 2026 BIO Partnering™ Overview Pre-Event Webinars Partnering Resources LOG IN TO BIO PARTNERING Participating Companies All Partnering Companies … Amgen Genentech Boehringer Ingelheim Lilly Novo Nordisk Sanofi Academic Campus Apply for Academic Campus Exhibition Directory and Map Event Directory Exhibitor List Exhibitor In-Booth Events Event Map Exhibition Hours Exhibition Reception BIO Booths BIO Business Solutions® Pavilion BIO Member Lounge Networking BIO Receptions Other Events Social Spotlight Events Affiliate Events Application Special Experiences 5K and 1 Mile Course BIO Gives Back Headshot Lounge Matchday Loung … quired. Financial, legal, consulting (262) This field is required. Hedge/Mutual Fund (PM,Buy-Side Research) (1) This field is required. Independent Research Firm (2) This field is required. Individual Investor (1) This field is required. Institute, hospital research (134) This field is required. Investment bank (50) This field is required. Investor (buy-side or sell-side research) (149) This field is required. IT, information (144) This field is required. Medical device or te
Immorta Bio Appoints Pharmaceutical Industry Veteran Dr. Armin Rath as Chief Business Officer Home About Us Mission People Careers Science Science of Aging SenoVax™ StemCellRevivify™ Intellectual Property Publications News & Resources News Decks Pipeline Main Pipeline Contact Us About Mission People Careers Contact Science Science of Aging SenoVax™ StemCellRevivify™ Intellectual Property Publications News & Resources News Decks Pipeline Main Pipeline Contact Immorta Bio Appoints Pharmaceutical Industry Veteran Dr. Armin Rath as Chief Business Officer PR Newswire July 16, 2025 MIAMI BEA
Alexander Leithner's summary expanded: universal #Spytagged extracellular domain immobilizer | Michael Dustin posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By cli … stamante Eguiguren , Michael I. Barton) and funding agencies ( Austrian Science Fund FWF , BBSRC ) who made this work possible. Mixed-mobility supported lipid bilayers uncover the role of immobilized ICAM1 on T cell activation and immune synapse organization | PNAS pnas.org 47 Like Comment Share Copy LinkedIn Facebook X To view or add a comment, sign in More Relevant Posts Department of Biotechnology 125,135 followers 3mo Report this post NIBMG Kalyani , in collaboration with
Scientific Longevity Company Immorta Bio Appoints Former Ernst & Young Health Sciences Partner Howard Brooks to Corporate Board of Directors Home About Us Mission People Careers Science Science of Aging SenoVax™ StemCellRevivify™ Intellectual Property Publications News & Resources News Decks Pipeline Main Pipeline Contact Us About Mission People Careers Contact Science Science of Aging SenoVax™ StemCellRevivify™ Intellectual Property Publications News & Resources News Decks Pipeline Main Pipeline Contact Scientific Longevity Company Immorta Bio Appoints Former Ernst & Young Hea
Instagram See everyday moments from your close friends . Log into Instagram Mobile number, username or email Password Log in Forgot password? Log in with Facebook Create new account Meta About Blog Jobs Help API Privacy Terms Locations Popular Instagram Lite Meta AI Threads Contact Uploading & Non-Users Meta Verified English Down chevron icon Afrikaans العربية Čeština Dansk Deutsch Ελληνικά English English (UK) Español (España) Español فارسی Suomi Français עברית Bahasa Indonesia Italiano 日本語 한국어 Bahasa Melayu Norsk Nederlands Polski Português (Brasil) Português (Portugal) Русский Svenska ภ
Intellectual Property Home About Us Mission People Careers Science Science of Aging SenoVax™ StemCellRevivify™ Intellectual Property Publications News & Resources News Decks Pipeline Main Pipeline Contact Us About Mission People Careers Contact Science Science of Aging SenoVax™ StemCellRevivify™ Intellectual Property Publications News & Resources News Decks Pipeline Main Pipeline Contact Intellectual Property Robust IP Portfolio Across Senescence Science & Regenerative Medicine Immorta Bio commands a powerful and expanding patent estate that secures every strategic layer of our pla … cell-based immunotherapy Our IP covers development, manufacturing, and clinical application, giving Immorta Bio a unique leadership position at the frontier of regenerative and longevity medicine. # Patent Title Patent Number Priority Date 23 Treatment of Autoimmunity Using Personalized Mesenchymal Stem Cells 63/800866 May 6, 2025 22 Augmentation of Natural Killer Cell Number and Activity by Senolytic Therapies 63/789097 April 22, 2025 21 Systemic Rejuvenation Using Exosomes
JavaScript is disabled In order to continue, we need to verify that you're not a robot. This requires JavaScript. Enable JavaScript and then reload the page.
Immorta Bio's Senolytic Immunotherapy Extends Lifespan by 84% | Immorta Bio posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in,
Pioneering cellular therapies for age-related diseases | Article | Drug Target Review Your browser is not supported Sorry but it looks as if your browser is out of date. To get the best experience using our site we recommend that you upgrade or switch browsers. Find a solution Skip to main content Skip to navigation Site name Site name Mast navigation Become a member Sign In Search our site Search our site Search Menu Close menu Home News Oncology AI Topics Back to parent navigation item Topics Technology Resources Diseases Drugs and therapies Research and development Tools and techniques Busi … oVax this year,” he shares. Immorta Bio filed an Investigational New Drug (IND) application for SenoVax earlier in 2024 and plans to submit an IND application for Stem Cell Revivify in the coming months. He projects that clinical trials for these therapies will begin within the next year, with subsequent Phase I and II trials likely to follow. Ichim's work at Immorta Bio is focused on transforming the way we approach age-related diseases and cancer treatment. Through his pion … cks in TCR Discovery 2025-10-22T14:00:00 Sponsored by Wuxi Biologics Whitepaper Application note: Direct and Competitive Live Cell Antibody Binding 2024-01-09T09:30:19 Sponsored by Sartorius Article Advanced techniques in toxicity testing 2024-08-05T15:00:04 Sponsored by Molecular Devices Whitepaper Guide: Tips for Single Cell Isolation 2023-03-14T10:07:00 Sponsored by Bio-Techne Whitepaper Whitepaper: Serum-free and Animal-free Research 2023-03-28T11:38:32 Sponsored by Bio-T
VentureRadar 0){if($('#i_b_toggleMore').hasClass('active')){Search_Elastic();}else{Search_DeconstructSearchString();Search_Elastic(false);event.preventDefault();}}else{event.preventDefault();}}" onclick="this.removeAttribute('readonly');" ontouchstart="this.removeAttribute('readonly');" id="i_t_Search" name="VRSearch" readonly> All Ranked Organisation Names Apps and Links Homepage (myVR) Funding Deals Hub Similar Companies App Articles Manage Account Logout Login Free Sign-up Forgotten your password? By continuing, you agree to VentureRadar's Terms of Service , Privacy Policy and Cookie … de Therapies; Vaccines; Biotech Show more Show less Updates All Funding Insight Grant Award Conference Competition Research Website Traffic Trend Business InsighT 01 Dec 2020 Website traffic has increased in the past 3 months, up from a ranking of 676,733 to 376,314. Source: Data from alexa.com COVID-19 vaccine tracker - London School of Hygiene & Tropical Medicine Research Report 20 Sep 2020 [BioNTech; Fosun Pharma; Pfizer] listed among those developing/researching a COVID-1 … ene therapy to cost $850,000 per patient | Reuters Source: reuters.com The STEP Award (2011) Award 29 Nov 2011 Category Winner: Finances Source: The STEP Award (2011) Show less Funding Signals VENTURE FUNDED Venture-funding News Venture-funding News Venture-funding News Related Top Ranked Companies Lists Life Sciences Biologics Healthtech Sars-Cov-2 Vaccine Cancer Melanoma Immunotherapy Diagnostics Dna Rna Peptide Therapies Vaccines Biotech Website Archive 2022 2023 2024 2025 … search results. Please select a Type Funding Round Team Products & Technologies Grant Award Conference Competition Other {DETAIL_VALUE} Remove Upgrade for full access You have reached your free usage limit for today. Upgrade to a paid plan for: Unlimited search alerts 250 records per export Unlimited pages and searches Full Access from $ 60.00 per month Upgrade Now Your VentureRadar Business account is now active and your account information has been sent to … nditions Privacy Policy Cookie Policy Contact Us Twitter LinkedIn | Submit a Company Directory of Companies Login Free Sign-up for VentureRadar access or By continuing, you agree to VentureRadar's Terms of Service , Privacy Policy and Cookie Policy . Free Sign-up for VentureRadar access You must have cookies enabled to create an accou
You need to enable JavaScript to run this app. Loading...
Tietosuojavalintasi guce guce Tietosuojasi on meille tärkeää Tietosuojavalintojasi käytetään kaikissa Yahoo-konsernin tarjoamissa sivustoissa ja sovelluksissa. Yahoo käyttää evästekäytännöstämme ."> Evästeet Evästeiden (sekä vastaavien tekniikoiden, esimerkiksi verkkotallennuksen) avulla verkkosivustojen sovellusten ylläpitäjät voivat tallentaa ja lukea laitteesi tietoja. Lue lisää evästekäytännöstämme . evästeitä seuraaviin tarkoituksiin: tarjotaksemme sivustomme ja sovelluksemme sinulle todentaaksemme käyttäjät, estääksemme roskapostia ja väärinkäytöksiä sekä toteuttaaksemme tietoturvatoimia